Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Change in Account Payables (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Change in Account Payables for 3 consecutive years, with -$236000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 77.84% to -$236000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$982000.0, a 438.62% decrease, with the full-year FY2024 number at $146000.0, up 111.56% from a year prior.
  • Change in Account Payables was -$236000.0 for Q3 2025 at Mereo BioPharma, up from -$2.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $987000.0 in Q4 2023 to a low of -$2.3 million in Q2 2023.
  • A 3-year average of -$267454.5 and a median of $127000.0 in 2024 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 185.04% in 2025; the steepest drop was 909.54% in 2025.
  • Mereo BioPharma's Change in Account Payables stood at $987000.0 in 2023, then dropped by 14.59% to $843000.0 in 2024, then crashed by 128.0% to -$236000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Change in Account Payables are -$236000.0 (Q3 2025), -$2.0 million (Q2 2025), and $362000.0 (Q1 2025).